Daiichi Sankyo
Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review
If the new application is approved, it would expand the market for Enhertu to include about half of all metastatic breast cancers.
Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Datopotamab Deruxtecan for TNBC
The firms are evaluating the anti-TROP2 antibody-drug conjugate versus chemo for previously untreated TNBC patients who aren't eligible for checkpoint inhibitors.
Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms
Oncologists at ASCO cheered data showing the drug significantly cut the risk of disease progression or death, but experts wondered how existing HER2 testing paradigms will change in response.
UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients
Premium
The study, conducted at the University of Southampton, homed in on crown-like structures of immune cells on the border of body fat and tumor tissue as a biomarker for anti-HER2 drug response.
Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications
The Strata PATH trial is exploring new precision oncology indications for already marketed drugs, including for four Pfizer treatments.